Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5370163 | 1.00 | FKBP1A (0.48) | FKBP1AGAALTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL5558161 | 1.00 | FKBP1A (0.48) | FKBP1AGAALTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL2276952 | 0.86 | FKBP1A (0.54) | FKBP1ALTA4HALDH1A1KMT2A | |
| SCHEMBL2772367 | 0.85 | LTA4H (0.57) | FKBP1ALTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL2772130 | 0.85 | LTA4H (0.57) | FKBP1ALTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL11143053 | 0.85 | MAPT (0.51) | GAAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5370839 | 0.85 | MAPT (0.51) | GAAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL5373647 | 0.85 | MAPT (0.51) | GAAALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2772128 | 0.85 | LTA4H (0.57) | FKBP1ALTA4HALDH1A1SMN1; SMN2 | |
| SCHEMBL2770248 | 0.83 | LTA4H (0.67) | FKBP1ALTA4HALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841423-A2 | USE OF 1- BENZYL-1- HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3 HYDROXY-2-AMINO PROPIONIC ACID AMIDES AND RELATED COMPOUNDS AS ANALGESICS | Allergan, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7268228-B2 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | IMAGENE CO., LTD. (KR) | 2007-09-11 | — | — | US | disclosed |
| WO-2006081252-A2 | USE OF 1-BENZYL-1-HYDR0XY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS AS ANALGESICS | ALLERGAN, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-1309550-A4 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | CHEMBIONEX CO LTD (KR) | 2004-07-07 | — | — | EP | disclosed |
| US-20040030133-A1 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | IMAGENE CO. LTD. (KR) | 2004-02-12 | — | — | US | disclosed |
| EP-1309550-A1 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | Chembionex Co., Ltd (KR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012186-A1 | OPTICALLY ACTIVE AZIRIDINE-2-CARBOXYLATE DERIVATIVES AND A PROCESS FOR PREPARING THEM | CHEMBIONEX CO., LTD. (KR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030133-A1 | Optically active aziridine-2-carboxylate derivatives and a process for preparing them | HRH2, HRH1, DDC | FKBP1A 4716/4885GAA 1763/4885LTA4H 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.